The very slow roll of Bio­gen's Aduhelm: Neu­rol­o­gists weigh in on pa­tients, prac­tices and pay­ments amid on­go­ing me­dia storm

Five months af­ter the ap­proval of Bio­gen’s Aduhelm, the bad news just keeps pil­ing up for the Alzheimer’s drug. The con­fir­ma­tion yes­ter­day of a Bio­gen …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.